Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: Implications for direct-acting antiviral treatment

Journal of Clinical Microbiology

Volumn 52, Issue 11, 2014, Pages 4027-4029

  Guelfo, Javier R ^a,b   Macias, Juan ^a,b   Neukam, Karin ^a,b   Di Lello, Federico A ^a,c   Mira, Jose A ^a,b   Merchante, Nicolas ^a,b   Mancebo, María ^a,b   Nuñez Torres, Rocío ^a,b   Pineda, Juan A ^a,b   Real, Luis M ^a,b  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b Instituto de Biomedicina de Sevilla   (Spain)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENOME ANALYSIS; GENOTYPING TECHNIQUE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; MIDDLE AGED; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TREATMENT RESPONSE; VIRUS GENOME; CLASSIFICATION; COMPARATIVE STUDY; DNA SEQUENCE; EVALUATION STUDY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

EID: 84908315991     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02209-14     Document Type: Article

References (15)

1. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Scott J, Kalmeijer R, De La Rosa G, Sinha R, Beumont-Mauviel M. 2013. Simeprevir (TMC435) with peg-interferon α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient subpopulations in the PROMISE phase III trial. Hepatology 58:737A-738A. http://dx.doi.org/10.1002/hep.26858.
2. Jacobson I, Dore GJ, Foster GR, Fried MW, Radu M, Rafalskiy VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Kalmeijer R, Beumont-Mauviel M. 2013. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treat-ment-naive patients: results from QUEST-1, a phase III trial. J. Hepatol. 58(Suppl 1):S574. http://dx.doi.org/10.1016/S0168-8278(13)61424-5.
3. Lok AS, Gardiner DF, Hezode C, Lawitz EJ, Bourliere M, Everson GT, Marcellin P, Rodriguez-Torres M, Pol S, Serfaty L, Eley T, Huang SP, Li J, Wind-Rotolo M, Yu F, McPhee F, Grasela DM, Pasquinelli C. 2014. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J. Hepatol. 60:490-499. http://dx.doi.org/10.1016/j.jhep.2013.10.019.
4. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. 2012. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366:216-224. http://dx.doi.org/10.1056/NEJMoa1104430.
5. Poordad F, Manns MP, Marcellin P, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Kalmeijer R, Beumont-Mauviel M. 2013. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. Gastroenterology 144:S151.
6. Sarrazin C, Zeuzem S. 2010. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138:447-462. http://dx.doi.org/10.1053/j.gastro.2009.11.055.
7. Schneider MD, Sarrazin C. 2014. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res. 105:64-71. http://dx.doi.org/10.1016/j.antiviral.2014.02.011.
8. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM. 2014. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 370:211-221. http://dx.doi.org/10.1056/NEJMoa1306218.
9. Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Mullhaupt B, Schuchmann M, Bourliere M, Buti M, Roberts SK, Gane EJ, Stern JO, Vinisko R, Kukolj G, Gallivan JP, Bocher WO, Mensa FJ. 2013. Faldaprevir and deleobuvir for HCV genotype 1 infection. N. Engl. J. Med. 369:630-639. http://dx.doi.org/10.1056/NEJMoa1213557.
10. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, Gojobori T, Maertens G, Mizokami M, Nainan O, Netesov S, Nishioka K, Shin I, Simmonds TP, Smith D, Stuyver L, Weiner A. 1998. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch. Virol. 143:2493-2503.
11. Avó AP, Agua-Doce I, Andrade A, Padua E. 2013. Hepatitis C virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay. J. Med. Virol. 85:815-822. http://dx.doi.org/10.1002/jmv.23545.
12. Bouchardeau F, Cantaloube JF, Chevaliez S, Portal C, Razer A, Lefrere JJ, Pawlotsky JM, De Micco P, Laperche S. 2007. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J. Clin. Microbiol. 45:1140-1145. http://dx.doi.org/10.1128/JCM.01982-06.
13. Cai Q, Zhao Z, Liu Y, Shao X, Gao Z. 2013. Comparison of three different HCV genotyping methods: core, NS5B sequence analysis and line probe assay. Int. J. Mol. Med. 31:347-352.
14. Simmonds P, Smith DB, McOmish F, Yap PL, Kolberg J, Urdea MS, Holmes EC. 1994. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J. Gen. Virol. 75(Part 5):1053-1061. http://dx.doi.org/10.1099/0022-1317-75-5-1053.
15. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28:2731-2739. http://dx.doi.org/10.1093/molbev/msr121.